Telix heads to the US, as RayzeBio runs into problems
Supply continues to cause headaches for radiopharmaceutical developers.
Astra’s radiopharma Fusion
AstraZeneca's quiet, cautious work is followed by a $2bn takeover.
Bristol makes its radiopharma move
The group’s $4.1bn swoop for RayzeBio follows big deals from Novartis and Lilly.
